NASDAQ · Biotechnology

Mirati Therapeutics, Inc. (MRTX) Stock

$58.70 -0.17% NASDAQ: MRTX Healthcare

Mirati Therapeutics, Inc. is a U.S.-based biotechnology firm operating at the clinical stage, committed to identifying and developing treatments that target the genetic and immunological factors driving cancer progression.

Valuation

MetricValue
Price$58.70
Market Cap$4.12B
P/E Ratio-4.45
P/B Ratio3.31
P/S Ratio331.11
EPS (TTM)$-13.18
52-Week High$64.41
52-Week Low$27.30
Dividend Yield0.00%

Financials & Margins

MetricValue
ROE-61.91%
ROA-61.60%
ROCE-72.81%
Gross Margin95.18%
Operating Margin-6333.33%
Net Margin-6175.00%
Debt/Equity0.05
Current Ratio6.96

Annual Financials (USD)

Metric20182019202020212022
Revenue$13.0M$3.0M$13.0M$72.0M$12.0M
Operating Profit$-103.0M$-222.0M$-369.0M$-573.0M$-760.0M
Net Profit$-98.0M$-213.0M$-358.0M$-582.0M$-741.0M
EPS$-3.19$-5.69$-7.96$-11.21$-13.18
Op Margin-794.0%-6659.8%-2756.8%-795.1%-6108.0%

Balance Sheet (USD)

Metric20182019202020212022
Total Assets$228.0M$432.0M$1.5B$1.6B$1.2B
Total Liabilities$27.0M$50.0M$115.0M$192.0M$206.0M
Cash$223.0M$415.0M$1.4B$413.0M$235.0M
Borrowings$0$0$42.0M$46.0M$52.0M

Cash Flow (USD)

Metric20182019202020212022
Operating Cash Flow$-70.0M$-148.0M$-272.0M$-389.0M$-571.0M
Investing Cash Flow$-292.0M$-178.0M$-144.0M$-599.0M$221.0M
Financing Cash Flow$141.0M$338.0M$1.3B$505.0M$167.0M
Net Cash Flow$-75.0M$14.0M$839.0M$-472.0M$-178.0M
Free Cash Flow$-70.0M$-149.0M$-276.0M$-399.0M$-575.0M

Valuation & Return Ratios

MetricValue
PEG Ratio-0.39
EV / EBITDA-5.20
FCF Yield-13.97%
Quick Ratio6.94
Interest Coverage0.00
Return 1Y—
Return 3Y—
Return 5Y—

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
ALPNAlpine Immune Sciences, Inc. $64.97 +0.02% -101.52 $4.46B 0.00%
CBAYCymaBay Therapeutics, Inc. $32.48 +0.03% -32.81 $3.73B 0.00%
ISEEIVERIC bio, Inc. $39.95 +0.38% -27.55 $5.51B 0.00%
KDNYChinook Therapeutics, Inc. $40.39 +0.22% -14.07 $2.71B 0.00%
MORMorphoSys AG $18.96 +2.43% -11.96 $2.86B 0.00%

About Mirati Therapeutics, Inc.

Mirati Therapeutics, Inc. is a U.S.-based biotechnology firm operating at the clinical stage, committed to identifying and developing treatments that target the genetic and immunological factors driving cancer progression. Its pipeline features MRTX849, a KRAS G12C inhibitor currently undergoing Phase 1/2 clinical trials for a range of malignancies, including non-small cell lung, colorectal, and pancreatic cancers. Additionally, the company is advancing Sitravatinib, an investigational broad-spectrum kinase inhibitor, which has reached Phase 3 clinical trials specifically for non-small cell lung cancer. Mirati also has a KRAS G12D inhibitor program in its preclinical development phase. The company has forged a collaboration and licensing agreement with BeiGene, Ltd. for the development, manufacturing, and commercialization of sitravatinib. Established in 1995, Mirati Therapeutics, Inc. maintains its headquarters in San Diego, California.

Mirati Therapeutics, Inc. is headquartered in US.

Mirati Therapeutics, Inc. (MRTX) stock trades at $58.70 with a market capitalization of $4.12B. The stock is valued at a price-to-earnings (P/E) ratio of -4.45, price-to-book of 3.31, price-to-sales of 331.11. Over the past 52 weeks the stock has ranged between $27.30 and $64.41, and currently trades 8.9% below its 52-week high.

On profitability, Mirati Therapeutics, Inc. generates a return on equity (ROE) of -61.91%, return on capital employed of -72.81%, an operating margin of -6333.33%, a net profit margin of -6175.00%.

Official website: www.mirati.com

Related Healthcare Stocks

LLY Drug Manufacturers - General $1185.71 -0.52% JNJ Drug Manufacturers - General $259.24 +0.88% ABBV Drug Manufacturers - General $246.04 +0.89% UNH Medical - Healthcare Plans $407.08 +0.77% MRK Drug Manufacturers - General $128.57 +0.16% NVS Drug Manufacturers - General $158.83 -0.64% NVO Biotechnology $51.58 +1.22% TMO Medical - Diagnostics & Research $594.00 +2.41% AMGN Drug Manufacturers - General $387.64 -1.39% ABT Medical - Devices $108.03 +0.70% GILD Drug Manufacturers - General $132.73 -1.18% PFE Drug Manufacturers - General $26.74 +2.06%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens featuring this stock

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksNasdaq High ROE StocksAll stock screens
Run Stock Screener Investing Guides